essential thrombocythaemia

essential thrombocythaemia

A rare blood disorder featuring an excess of blood platelets with the increased risk of clotting of blood within the blood vessels (thrombosis). The cause is unknown.
Mentioned in ?
References in periodicals archive ?
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
Ph chromosome-negative neoplasms include polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), whereas chronic myeloid leukaemia (CML) comprises Ph chromosome-positive neoplasms.
Pt is diagnosed as MPD: Essential Thrombocythaemia. Patient is prescribed Hydroxyurea 500mg bd along with ferrous sulphate and Folic acid, got discharged on 12-10-2011.
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
Patients and Methods: Ninety three consecutive patients of Polycythaemia vera (PV), Essential thrombocythaemia (ET) and Idiopathic myelofibrosis (IMF) diagnosed by the conventional haematological criteria were included in the study.
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90.
Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol 2003;123:513-6.
AGRYLIN is a treatment for essential thrombocythaemia (ET), a chronic disorder of bone marrow, which is associated with the increased production of blood platelets.
QA DISTANT relative has been diagnosed with a condition called essential thrombocythaemia and has a platelet count of 1000.
At its most recent meeting, on 26-27 October, the Committee for Orphan Medicinal Products issued six positive opinions on the designation of orphan medicinal products, for conditioning treatment prior to hematopoietic progenitor cell transplantation; erythema nodosum leprosum or type II lepra reactions; essential thrombocythaemia; Huntington's Disease; primary and certain forms of secondary pulmonary hypertension; and tyrosinaemia type 1.These will now be forwarded to the European Commission for the formal decision-making process.

Full browser ?